Several human genetic disorders of hemoglobin have risen in frequency because of the protection they offer against death from malaria, sickle-cell anemia being a canonical example. Here we address the issue of why this highly protective mutant, present at high frequencies in subSaharan Africa, is uncommon in Mediterranean populations that instead harbor a diverse range of thalassemic hemoglobin disorders. We demonstrate that these contrasting profiles of malaria-protective alleles can arise and be stably maintained by two well-documented phenomena: an alleviation of the clinical severity of ␣-and ␤-thalassemia in compound thalassemic genotypes and a cancellation of malaria protection when ␣-thalassemia and the sickle-cell trait are coinherited. The complex distribution of globin mutants across Africa and the Mediterranean can therefore be explained by their specific intracellular interactions.
I
n 1949, Haldane (1) proposed the malaria hypothesis to account for the high frequency of thalassemic blood disorders observed in Mediterranean populations. He suggested that carriers of thalassemic genes might enjoy protection against malaria, which exacted a very high mortality in Southern Europe right up to the end of the Second World War. Such malaria-protective properties have since been demonstrated for a range of genetic disorders of hemoglobin (Hb), including sickle-cell (HbS) disease. The frequencies that these hemoglobinopathies have reached in populations living in malarious regions (2) testify to the profound inf luence that malaria has had on recent human evolution and present a significant public health burden in many nations ill equipped to provide adequate care (3) .
Inherited disorders of hemoglobin are caused by mutations in genes encoding its ␣-or ␤-globin subunits. These mutations may result in structural alterations that interfere with function or stability, as exemplified at the ␤-globin locus by the sickle-cell allele (␤ S ), or may reduce the rate at which one or another subunit is produced, leading to either ␣-or ␤-thalassemia. The latter are extremely heterogeneous: ␣-thalassemias are subdivided into ␣ ϩ , in which one of the linked pair of ␣-globin genes found on chromosome 16 is deleted or inactivated by a point mutation, and ␣ o , in which both genes are lost*. Similarly, the ␤-thalassemic mutations (␤ T ) are subdivided into ␤ o , in which there is no output of ␤-chains at all, and ␤ ϩ or ␤ ϩϩ , in which there is, respectively, either a moderate to severe or extremely mild reduction in ␤-chain production (4).
The global distribution of these various globin gene mutations poses a number of interesting and important conundrums. Here we focus on the contrast between subSaharan Africa and the Mediterranean: The former is dominated by the ␤ S and ␣ ϩ alleles, yet ␤ S is uncommon in the Mediterranean where ␤ T , ␣ ϩ , and ␣ 0 have a significant presence. The diverse range of regionally specific ␤-thalassemic mutations seen across the Mediterranean, Middle East, and Asia indicates that they are generated frequently in malarious regions; their absence from most of subSaharan Africa implies that the ␤ S allele has outcompeted all preexisting ␤-thalassemic alleles at the ␤-globin locus. There is good evidence from haplotypic analyses (5, 6) that ␤ S did reach the Mediterranean from Africa, so it remains a mystery as to why it has not spread more extensively through this region.
Alpha and beta globin must combine to form functional hemoglobin, so it seems likely that the phenotypic outcome of a mutation at the ␤-globin locus would vary depending on the associated ␣-globin genotype and vice versa. There now exist two well-documented examples of such epistasis, as outlined below, which we believe may provide an answer to the question of why different suites of hemoglobin mutations predominate in particular geographical regions.
The pathophysiology of the thalassemias derives largely from the accumulation of unpaired globin subunits produced by the unaffected gene, which have a severely detrimental effect on erythrocytes and erythrocyte precursors. An extensive literature suggests that the coinheritance of both ␣-and ␤-thalassemia can ameliorate the severity of these hemoglobin disorders by reducing the degree of imbalance in globin chain synthesis (4, 7). There is also growing evidence that a negative epistatic interaction exists between ␣ ϩ -thalassemia and the sickle-cell trait (8, 9) , such that the coinheritance of both traits cancels out their malaria-protective effect. This cancellation may be because the malaria protectiveness of HbS is directly linked to its concentration in erythrocytes, which is lowered in individuals possessing both the sickle-cell trait and ␣-thalassemia, possibly because of the smaller pool of ␣-globin preferentially binding to normal ␤-globin (10).
Results and Discussion
Epistatic Interactions Generate Contrasting Allelic Profiles. To explore the population-level implications of these two intracellular interactions, we developed a simple population genetic framework (see Methods) with three alleles at the ␣-globin locus (WT, ␣ ϩ , and ␣ 0 ) and four alleles at the ␤-globin locus (WT, the sickle allele ␤ S , ␤ 0 , and ␤ ϩ ). Each genotype was assigned a mortality rate that was the sum of the mortality associated with blood disorder severity (q) and the mortality 
due to death from malaria (r); these could be modified to include a cancellation of malaria protection for those who coinherit ␣-thalassemia and the sickle-cell trait and an amelioration of the blood disorder for those with both ␣-and ␤-thalassemia (see SI Appendix). Our analysis indicates that two evolutionary outcomes are possible within this dynamical system. When the sickle allele (␤ S ) enters the population early, it can displace ␤ 0 and ␤ ϩ , leading to an equilibrium state where ␤ S and ␣ ϩ are the only variant alleles present, and negative epistasis between the two prevents ␣ ϩ reaching unrealistically high frequencies, as shown in Fig. 1A .
† However, if the entry of ␤ S is delayed, the population may be driven toward an alternative stable state in which ␤ S is lost and ␤ ϩ dominates; here ␣ ϩ and ␣ 0 eventually drive out WT ␣ (Fig. 1B) . In essence, there are two attractors in the phase space of this evolutionary dynamical system as represented by points A and B within the 3D construct shown in Fig. 1C . We propose that the presentday situation in Africa [where ␣ ϩ coexists with ␤ S but ␣ ϩ frequencies do not exceed 50% (2)] lies very close to the attractor A, whereas the Mediterranean scenario [e.g., 17%
␤-thalassemia and 14% ␣-thalassemia in Cyprus, with well documented ␣ 0 (2)] is a point on the trajectory toward attractor B. Fig. 2 illustrates proposed subSaharan and Mediterranean behaviors over the short term, differentiated by the time of entry of the sickle-cell allele.
The rarity of the sickle-cell trait in the Mediterranean is generally ascribed to its recent import from Africa into populations that already contained thalassemia (5, 11) . However, our results indicate that the observed patterns are more robustly explained by the active exclusion of ␤ S through intracellular interactions between globin mutants rather than by invoking a recent entry of ␤ S into the population. Fig. 3 illustrates how epistatic interactions involving ␣ thalassemia can place populations starting with relatively low levels of ␤ ϩ on a trajectory where ␤ S is excluded, thus permitting ␤ S to have arrived early on in the history of malaria in the Mediterranean and yet only be at negligible levels today. As indicated by the loop in Fig. 3D , ␤ ϩ may suffer a decline before recovering to drive out ␤ S . Fig. 4 shows the relative frequencies of ␣ ϩ and ␤ ϩ required to prevent ␤ S invasion, illustrating the dramatic reduction in these frequencies that epistasis can bring about. Finally, the range of plausible ␤ ϩ alleles (in terms of their clinical severity and the degree of protection they offer against malaria) which could resist a ␤ S invasion is greatly increased by the inclusion of epistasis (see Fig.  S1 of the SI Appendix). † This concurs with a simpler model considering only the effect of negative epistasis between ␣ ϩ -thalassemia and the sickle-cell trait in subSaharan Africa (8) . As noted in that paper, this result offers a compelling explanation for the observation that frequencies of ␣ ϩ -thalassemia in subSaharan Africa do not exceed 50%. Table S1 of the SI Appendix. Table S1 of the SI Appendix, and malaria was assumed to exert an excess mortality of 0.005 yrs Ϫ1 .
compound heterozygote for ␣ ϩ and ␣ 0 ) preclude the possibility of both types of ␣-thalassemia coexisting stably at equilibrium. Our results indicate that ␣ 0 can be maintained indefinitely (Fig. 1B) , provided that the ␣ ϩ ␣ 0 genotype is strongly protective against malaria and that coinheriting ␤-thalassemia reduces the severity of HbH disease without reducing the protection offered against malaria. There is evidence for a positive interaction between ␤ thalassemia and HbH disease (4) at the level of the blood disorder; few studies have considered the possible protective effect of HbH against malaria, but some in vitro evidence points to HbH RBCs being particularly refractory to the multiplication of the malaria parasite (13) . Additionally, individuals with both HbH disease and ␤-thalassemia, although benefiting from more-balanced globin chain synthesis and increased (even to normal) RBC survival time compared with those with HbH disease alone, still display certain erythrocyte membrane abnormalities associated with full-blown HbH disease (4) . Such membrane abnormalities might well have an effect on the suitability of these cells for invasion by Plasmodium falciparum and hence provide a protective mechanism. The presence of ␤ ϩ may thus be of importance to the maintenance of ␣ 0 ; the lack of ␤ ϩ in subSaharan Africa, compounded with negative epistasis with the sickle-cell trait, may explain why ␣ 0 is not found there.
Absence of the ␤ ؉ Allele in SubSaharan Africa. Within our framework, a population that has experienced an early entry of ␤ S cannot maintain ␤ ϩ . This finding is consistent with most of subSaharan Africa, with the notable exception of parts of Liberia (14) , which harbor a ␤-thalassemic allele (␤ ϩϩ ) with a much milder clinical phenotype than those of the Mediterranean (15) . The sickle-beta thalassemia phenotype in this population is also mild (16) . Our analysis shows that such a ␤ ϩϩ allele would take an extremely long time to be driven out by ␤ S (see SI Appendix) which could account for its persistence. A small number of West African populations also display significant frequencies of the ␤-globin structural variant that gives rise to hemoglobin C (HbC). HbC heterozygotes have been shown to be protected against cerebral malaria (9, 17) but are unlikely to enjoy as much of an advantage as ␤ S heterozygotes, who are strongly protected against all forms of severe malaria (9) . However, the homozygous state is relatively mild (as a hematological condition) and appears also to offer protection against malaria (18, 19) . For these reasons, HbC   Fig. 4 . The effects of positive and negative epistasis on the levels of the thalassemias required to resist invasion by ␤ S . To remove positive epistasis, all compound thalassemic genotypes were given the higher of the two mortality rates associated with their constituent individual thalassemia genotypes (parameter values given in Table S1 of the SI Appendix). To remove negative epistasis, all genotypes heterozygous for ␤ S were given 94% protection against death from malaria. ''Noninvasion'' of ␤ S was defined as follows: after 2,000 generations, ␤ S (initial frequency 0.0001) must be at a frequency below 0.001 and not increasing in frequency. In the case of ''no epistasis'', ␤ S is only prevented from invading the population when the frequency of ␤ ϩ is 0.9999 and ␤ S is introduced at a frequency of 0.0001; there is no normal ␤-globin present.
may be slowly increasing in frequency (20) , but it is currently confined to a very restricted area.
Malaria Protection in Compound Thalassemic
Genotypes. An important property of the intracellular interactions included in our framework is that although coinheritance of ␣-and ␤-thalassemia ameliorates their respective hematological disorders, the compound thalassemic genotypes retain malaria protection. The cellular mechanisms involved in the protection against malaria mediated by the thalassemias are still not clear (21) . Thalassemic red cells are small and deficient in hemoglobin, and the red cell count is considerably elevated; it has recently been suggested that the latter may offer some protection against the often profound anemia of acute malaria (22) . In compound heterozygotes for ␣-and ␤-thalassemia, ␣ ϩ ␣/␤ T ␤, the hematological changes are not significantly different from those of ␤-thalassemia heterozygotes, although the genotype ␣ ϩ ␣ ϩ /␤ T ␤ is associated with larger and better hemoglobinized red cells (4) . The red cells of ␤ thalassemia heterozygotes also have abnormal membrane function, including increased binding of malarial antibodies (23) , presumably reflecting well-defined metabolic defects (24); very similar abnormalities are found in compound heterozygotes for ␣-and ␤-thalassemia (25) . Thus, unlike the cancellation of malaria protection mediated by negative epistasis between ␣-thalassemia and HbS, there are no obvious hematological or biochemical differences between the red cells of ␤-thalassemia heterozygotes and compound heterozygotes for ␣-and ␤-thalassemia that would be likely to have an effect on diminishing malaria resistance.
Conclusion
Positive epistasis between the ␣-and ␤-thalassemias has been well studied at the molecular and individual level. Here we show that, provided a degree of malaria protection is retained in the compound thalassemic genotypes, such epistasis can have profound population genetic consequences, enabling populations containing a threshold level of ␣-and ␤-thalassemia to resist invasion by the sickle-cell allele. We have also considered the recently described phenomenon of negative epistasis between ␣-thalassemia and the sickle-cell trait, which can similarly assist in the exclusion of the sickle-cell allele from a thalassemiacontaining population but which more importantly enables our framework to realistically capture subSaharan allele frequencies. In addition to offering a robust solution to the question of why the highly protective sickle-cell allele has not penetrated Mediterranean populations, our demonstration that contrasting sets of hemoglobin disorders can be stably maintained within a single framework provides a general model for the evolution of distinct subsets of malaria-protective hemoglobinopathies as observed in other global regions.
We stress that it is only because the phenotypes of globin gene variants have been so exhaustively studied that we have been able here to link their recognized intracellular interactions to observed population genetic patterns; our conclusions thus strongly underscore the importance of phenotypic information, without which patterns of genetic variation alone can give limited insight.
Methods
The rate of change of frequency of each genotype, yij, with respect to time was given by the following equation:
where is the mortality rate of the WT genotype in the absence of malaria; m is the extra mortality imposed by malaria on the population; qij is the relative blood disorder associated mortality of genotype ij; and r ij is the relative susceptibility to death from malaria of genotype ij. is the total birth rate [equal to Α iϭ1, jϭ1 iϭ6, jϭ10 y ij ͑q ij ϩ r ij m ͒], which is apportioned according to the frequencies of allelic combinations at the ␣-and ␤-globin loci, which together define genotype ij. ␣1, ␣2, ␣3 and ␤1, ␤2, ␤3, ␤4 are the frequencies of all of the possible alleles at the ␣-and ␤-globin loci respectively, and the functions f i(␣1, ␣2, ␣3) and fj(␤1, ␤2, ␤3, ␤4) describe the frequencies of the different potential genotypes at the alpha ( f i) and beta ( fj) globin loci (see SI Appendix for details). We used Markov Chain Monte Carlo methods to determine the ranges of mortality rate parameters that can generate the equilibrium outcomes of interest within our framework (see SI Appendix), given the reasonable assumption that ␤ ϩ -thalassemia is costly in the homozygous state and not as malaria protective as ␤ S . This analysis confirmed a role for negative epistasis between ␣-thalassemia and the sickle-cell trait and for positive epistasis between ␣-and ␤-thalassemia. The values given in Table S1 of the SI Appendix represent just one plausible set of mortality rate parameters [where we have used malaria protectiveness estimates for the ␣␣ ␤␤ S , ␣ ϩ ␣ ␤␤, and ␣ ϩ ␣ ␤␤ S genotypes from the literature (9)].
